The goal of blood pressure in the hypertensive patient with diabetes is defined: now the challenge is go from recommendations to practice

[1]  P. Peduzzi,et al.  Combined angiotensin inhibition for the treatment of diabetic nephropathy. , 2013, The New England journal of medicine.

[2]  Wei-Chih Liao,et al.  Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis , 2013, BMJ.

[3]  M. Woodward,et al.  Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials , 2013, BMJ.

[4]  C. Leitão,et al.  Hypertension management algorithm for type 2 diabetic patients applied in primary care , 2013, Diabetology & Metabolic Syndrome.

[5]  Martin McKee,et al.  Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. , 2013, JAMA.

[6]  P. Libby.  Mechanisms of acute coronary syndromes. , 2013, The New England journal of medicine.

[7]  P. López-Jaramillo,et al.  Mechanisms of acute coronary syndromes. , 2013, New England Journal of Medicine.

[8]  Jeroen J. Bax,et al.  2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). , 2007, Blood pressure.

[9]  W. Aronow.  Editorial on hemoglobin A1c, blood pressure, and low-density lipoprotein cholesterol goals in diabetics. , 2013, World Journal of Cardiology.

[10]  P. Libby.  Mechanisms of acute coronary syndromes and their implications for therapy. , 2013, The New England journal of medicine.

[11]  P. López-Jaramillo,et al.  [Latin American consensus on hypertension in patients with diabetes type 2 and metabolic syndrome]. , 2014, Arquivos brasileiros de endocrinologia e metabologia.

[12]  V. Basevi.  Standards of Medical Care in Diabetes—2013 , 2012, Diabetes Care.

[13]  M. Woodward,et al.  Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis , 2012, The Lancet.

[14]  M. Banach,et al.  Blood Pressure J-Curve: Current Concepts , 2012, Current Hypertension Reports.

[15]  K. Khunti,et al.  Association of systolic and diastolic blood pressure and all cause mortality in people with newly diagnosed type 2 diabetes: retrospective cohort study , 2012, BMJ : British Medical Journal.

[16]  J. Sowers,et al.  Evidence‐Based Hypertension Treatment in Patients With Diabetes , 2012, Journal of clinical hypertension.

[17]  J. Chan,et al.  Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study , 2011, Diabetologia.

[18]  T. Gaziano.  Accurate hypertension diagnosis is key in efficient control , 2011, The Lancet.

[19]  Martin McKee,et al.  Priority actions for the non-communicable disease crisis , 2011, The Lancet.

[20]  J. Gross,et al.  Diabetic Retinopathy Predicts All-Cause Mortality and Cardiovascular Events in Both Type 1 and 2 Diabetes , 2011, Diabetes Care.

[21]  M. S. Kirkman,et al.  Response to Comment on: American Diabetes Association. Standards of Medical Care in Diabetes—2011. Diabetes Care 2011;34(Suppl. 1):S11–S61 , 2011, Diabetes Care.

[22]  P. López-Jaramillo,et al.  Epidemic of cardiometabolic diseases: a Latin American point of view , 2011, Therapeutic advances in cardiovascular disease.

[23]  L. Ruilope,et al.  Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. , 2011, The New England journal of medicine.

[24]  R. Simó,et al.  Prevalence and risk factors accounting for true silent myocardial ischemia: a pilot case-control study comparing type 2 diabetic with non-diabetic control subjects , 2011, Cardiovascular diabetology.

[25]  M. Banach,et al.  Editorial [Hot topic: Controversies in Hypertension Treatment (Guest Editors: Maciej Banach, Sverre E. Kjeldsen and Krzysztof Narkiewicz)] , 2010 .

[26]  S. Yusuf,et al.  Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study , 2010, The Lancet.

[27]  G. Bakris,et al.  Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. , 2010, JAMA.

[28]  Kevin A Peterson,et al.  Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus , 2011 .

[29]  K. Reynolds,et al.  Premature deaths attributable to blood pressure in China: a prospective cohort study , 2009, The Lancet.

[30]  Shah Ebrahim,et al.  Fasting Blood Glucose and the Risk of Stroke and Myocardial Infarction , 2009, Circulation.

[31]  Giuseppe Mancia,et al.  Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document , 2009, Blood pressure.

[32]  Rury R Holman,et al.  Long-term follow-up after tight control of blood pressure in type 2 diabetes. , 2008, The New England journal of medicine.

[33]  R. Holman,et al.  10-year follow-up of intensive glucose control in type 2 diabetes. , 2008, The New England journal of medicine.

[34]  Li-sheng Liu,et al.  Blood-pressure-related disease is a global health priority. , 2008, Journal of Hypertension.

[35]  P. López-Jaramillo.  Defining the research priorities to fight the burden of cardiovascular diseases in Latin America. , 2008, Journal of hypertension.

[36]  S. Yusuf,et al.  Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial , 2008, The Lancet.

[37]  P. López-Jaramillo,et al.  Cardiovascular prevention in high-risk patients with type 2 diabetes mellitus: when to start it? , 2008, European heart journal.

[38]  A. Rodgers,et al.  Global burden of blood-pressure-related disease, 2001 , 2008, The Lancet.

[39]  S. Yusuf,et al.  Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial). , 2012, Journal of the American College of Cardiology.

[40]  S. Yusuf,et al.  Telmisartan, ramipril, or both in patients at high risk for vascular events. , 2008, The New England journal of medicine.

[41]  Yuh-Min Song,et al.  Faculty Opinions recommendation of Resolution of asymptomatic myocardial ischemia in patients with type 2 diabetes in the Detection of Ischemia in Asymptomatic Diabetics (DIAD) study. , 2007 .

[42]  R. Klein,et al.  Erratum: Diabetic retinopathy and the risk of coronary heart disease: The Atherosclerosis Risk in Communities Study (Diabetes Care (2007) 30, (1742-1746)) , 2007 .

[43]  Seppo Lehto,et al.  Retinopathy Predicts Cardiovascular Mortality in Type 2 Diabetic Men and Women , 2007, Diabetes Care.

[44]  A. Dominiczak,et al.  2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) , 2007, European heart journal.

[45]  Piotr Ponikowski,et al.  2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). , 2007, European heart journal.

[46]  J. Craig,et al.  Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. , 2006, The Cochrane database of systematic reviews.

[47]  Mark Woodward,et al.  Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies , 2005, BMJ : British Medical Journal.

[48]  J. Rouleau,et al.  Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. , 2005, Journal of the American Society of Nephrology : JASN.

[49]  P. Valensi,et al.  Markers for silent myocardial ischemia in diabetes. Are they helpful? , 2005, Diabetes & metabolism.

[50]  C. Baxter,et al.  Detection of silent myocardial ischemia in asymptomatic diabetic subjects: the DIAD study. , 2005, Diabetes care.

[51]  E. Barrett,et al.  Erratum: Detection of Ischemia in Asymptomatic Diabetics (DIAD) investigators: Detection of silent myocardial ischemia in asymptomatic diabetic subjects: The DIAD study (Diabetes Care (2004) 27 (1954-1961)) , 2005 .

[52]  G. Mancia,et al.  Clinical Outcomes in the Diabetes Cohort of the International Verapamil SR-Trandolapril Study , 2004, Hypertension.

[53]  Alan D. Lopez,et al.  the Global Burden of Disease , 2004 .

[54]  Charles E McCulloch,et al.  Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. , 2004, The New England journal of medicine.

[55]  S. Yusuf,et al.  Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study , 2004, The Lancet.

[56]  E. Barrett,et al.  Detection of silent myocardial ischemia in asymptomatic diabetic subjects: the DIAD study. , 2004, Diabetes care.

[57]  F. Turnbull.  Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials , 2003, The Lancet.

[58]  P. Raskin,et al.  Treatment of hypertension in adults with diabetes. , 2003, Diabetes care.

[59]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[60]  M. Pfeffer,et al.  Cardiovascular Outcomes in the Irbesartan Diabetic Nephropathy Trial of Patients with Type 2 Diabetes and Overt Nephropathy , 2003, Annals of Internal Medicine.

[61]  Robert M. Anderson,et al.  Prevention or delay of type 2 diabetes. , 2004, Diabetes care.

[62]  Ethan M Balk,et al.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[63]  P. Mehler,et al.  Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. , 2002, Kidney international.

[64]  S. Yusuf,et al.  Global burden of cardiovascular diseases: Part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. , 2001, Circulation.

[65]  S. Yusuf,et al.  Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. , 2001, Circulation.

[66]  E. Frohlich,et al.  Diabetes, Hypertension, and Cardiovascular Disease: An Update , 2001, Hypertension.

[67]  John S Yudkin,et al.  Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study , 2000, BMJ : British Medical Journal.

[68]  R. Holman,et al.  Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study , 2000, BMJ : British Medical Journal.

[69]  S. Yusuf,et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[70]  S. Yusuf,et al.  Emerging epidemic of cardiovascular disease in developing countries. , 1999, Circulation.

[71]  P. Raskin,et al.  Report of the expert committee on the diagnosis and classification of diabetes mellitus. , 1999, Diabetes care.

[72]  E. Grossman.  Does the ‘J-curve’ still hold in the post ‘HOT’ era? , 1998, Journal of Human Hypertension.

[73]  H. Ibsen.  Intensive blood pressure lowering warranted. Results of the HOT study: an epitaph for the J-curve concept in hypertension , 1998, Journal of Human Hypertension.

[74]  Philip D. Harvey,et al.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 , 1998, BMJ.

[75]  R. Holman,et al.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.

[76]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[77]  R. Holman,et al.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. , 1998 .

[78]  Uk-Prospective-Diabetes-Study-Group.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.

[79]  J. Neaton,et al.  Sixteen-year coronary mortality in black and white men with diabetes screened for the Multiple Risk Factor Intervention Trial (MRFIT). , 1998, International journal of epidemiology.

[80]  Joël Ménard,et al.  Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial , 1998, The Lancet.

[81]  M. Fantone,et al.  Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus , 1997, Diabetes Care.

[82]  R. Schrier,et al.  Appropriate Blood Pressure Control in NIDDM (ABCD) Trial , 1996, Diabetologia.

[83]  J. Neaton,et al.  Diabetes, Other Risk Factors, and 12-Yr Cardiovascular Mortality for Men Screened in the Multiple Risk Factor Intervention Trial , 1993, Diabetes Care.

[84]  C. Mulrow,et al.  The J-curve phenomenon and the treatment of hypertension. , 1991, JAMA.

[85]  P. Wilson,et al.  The epidemiology of impaired glucose tolerance and hypertension. , 1991, American heart journal.

[86]  C. Mulrow,et al.  The J-curve phenomenon and the treatment of hypertension. Is there a point beyond which pressure reduction is dangerous? , 1991, JAMA.

[87]  J. Cutler,et al.  The 1984 Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. , 1984, Archives of internal medicine.

[88]  C. Pepine,et al.  Blood pressure lowering in patients with diabetes—one level might not fit all , 2011, Nature Reviews Cardiology.

[89]  W. Elliott.  Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document , 2010 .

[90]  Y. Jang,et al.  Standards of Medical Care in Diabetes-2010 by the American Diabetes Association: Prevention and Management of Cardiovascular Disease , 2010 .

[91]  G. Braden.  Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. , 2003 .

[92]  Kdoqi Disclaimer.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[93]  R. Weinshilboum,et al.  The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. , 1997, Archives of internal medicine.

[94]  Detection.  The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI) , 1997 .

[95]  The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V) , 1993, Archives of internal medicine.

[96]  A. Nissinen,et al.  Blood pressure changes as predictors of future mortality in the seven countries study. , 1991, Journal of human hypertension.